GI Dynamics (ASX:GID) said Swiss and German regulators took the 1st steps toward reimbursement in those countries for its EndoBarrier weight loss and diabetes device.

Lexington-Mass.-based GI Dynamics said the German Institute of Medical Documentation & Information granted preliminary codes for the EndoBarrier to treat Type II diabetes and/or obesity. In Switzerland, the Federal Office for Statistics published a unique code for EndoBarrier implantation, according to a press release.

"The designation and implementation of these codes allow government authorities to track costs and align reimbursement codes for EndoBarrier therapy," according to the release. "Once data on a sufficient number of EndoBarrier procedures have been accumulated, these will be evaluated and the company expects that the codes will be mapped to procedure codes and costs consistent with EndoBarrier therapy."